TC BioPharm Files Form 6-K for September 2025

TL;DR

TC BioPharm (Holdings) plc filed a 6-K on 9/2/25, confirming its foreign private issuer status.

AI Summary

TC BioPharm (Holdings) plc, a biopharmaceutical company, filed a Form 6-K on September 2, 2025. This report is for the month of September 2025 and indicates the company is a foreign private issuer filing under the 1934 Act. The company's principal executive offices are located in Holytown, Scotland, United Kingdom.

Why It Matters

This filing serves as an update for investors regarding TC BioPharm's regulatory status and operational location as a foreign private issuer.

Risk Assessment

Risk Level: low — This filing is a routine administrative report and does not contain new financial or operational information that would typically indicate significant risk.

Key Players & Entities

• TC BioPharm (Holdings) plc (company) — Registrant
• September 2, 2025 (date) — Filing Date
• 001-41231 (other) — Commission File Number
• Holytown, Scotland, United Kingdom (location) — Principal Executive Offices

FAQ

Filing Documents

• form6-k.htm (6-K) — 116KB
• 0001641172-25-026207.txt ( ) — 117KB

financial statements are laid before the Company

financial statements are laid before the Company. 851,757,945 80,492,000 8,236,000 Resolution 4: THAT the Audit Committee is authorized to determine the remuneration of the U.K. statutory auditor for the year ending December 31, 2025. 833,429,945 99,024,000 8,032,000 Resolution 5 : THAT each of the ordinary shares of £0.0001 each in the capital of the Company be and are hereby subdivided and reclassified into 1 ordinary share of £0.000001 and 1 B deferred share ( B Deferred Share ) of £0.000099 each in the capital of the Company such B Deferred Shares to have the rights set out in the new article 7B referred to Resolution 8. 790,781,945 117,144,000 32,560,000 Resolution For Against Withheld Resolution 6 : THAT , in accordance with s551 of the Companies act 2006 ( Act ), the directors of the Company or a duly authorised committee of the directors be generally and unconditionally authorised to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company ( Rights ) up to an aggregate nominal amount of £200,000,000 for a period expiring (unless previously renewed, varied, or revoked by the Company in general meeting) five years after the date on which this Resolution is passed, save that the Company may, before such expiry, make an offer or agreement which would or might require shares to be allotted or Rights to be granted and the directors may allot shares or grant Rights in pursuance of such offer or agreement notwithstanding that the authority conferred by this Resolution has expired. The authority granted by this Resolution shall be in addition to all existing authorities to allot any shares of the Company and to grant rights to subscribe for or convert any securities into shares in the Company previously granted to the directors pursuant to section 551 of the Act and without prejudice to any allotment of shares or grant of rights already made or offered or

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TC BIOPHARM (HOLDINGS) PLC Date: September 2, 2025 By: /s/ Martin Thorp Martin Thorp Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR